stockrow
Friday 6 November 2026
Export CLNN’s income statement to Excel — free account
Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024.
- Revenue
- +273.3%
- EPS
- +135.2%
- Free cash flow
- −16.6%
- Total debt
- −60.3%
Quarter to September 2026, against a year earlier
3.85
0.12
−3.02%
Follow CLNN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
289.36 | 428.39 | 387.20 | 224.23 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(12.06) | (12.68) | (29.47) | (11.56) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
331.12 | 506.01 | 431.06 | 208.98 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.57) | (3.75) | (5.34) | (3.01) | |
EV/FCF |
(3.56) | (3.75) | (5.32) | (2.99) | |
Quick Ratio |
0.48 | 0.88 | 2.00 | 0.58 | |
Current Ratio |
0.83 | 1.94 | 3.07 | 0.85 | |
Net Debt/EBITDA |
(1.17) | (6.10) | (1.73) | 0.60 | |
Debt/Assets |
74.68% | 75.42% | 79.47% | 28.25% | |
Debt/Equity |
(0.77) | (0.87) | (0.74) | (0.42) | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.52 | 0.56 | 0.19 | (1.18) | |
Capex/Depreciation |
(0.08) | 0.00 | 0.00 | (0.15) | |
Interest Coverage |
(10.05) | (2.61) | (7.69) | (9.54) | |
Research and Development Expense of Revenue |
7,146.75% | 2,193.33% | 3,856.67% | 7,941.07% | |
Selling, General and Administrative Expense of Revenue |
2,657.14% | 11,646.67% | 2,144.44% | 3,464.29% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,772.73% | 8,746.67% | 1,155.56% | 1,926.79% | |
Graham Net Nets |
(0.46) | (0.48) | (0.43) | (0.42) | |
Graham Number |
10.22 | 10.78 | 12.55 | 7.74 | |
Earnings Yield |
(44.29%) | (64.91%) | (56.82%) | (57.62%) | |
Free Cash Flow Yield |
(32.12%) | (31.54%) | (20.91%) | (31.15%) | |
Revenue per Share |
0.01 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(0.49) | (0.39) | (0.21) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.49) | (0.39) | (0.21) | (0.36) | |
Cash per Share |
0.53 | 0.51 | 0.78 | 0.76 | |
Shareholders Equity per Share |
(1.78) | (1.62) | (2.00) | (1.13) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.78) | (1.62) | (2.00) | (1.13) | |
Free Cash Flow |
(4.83) | (4.53) | (2.59) | (4.67) | |
Working Capital |
(1.80) | 6.29 | 10.06 | (2.62) | |
Capital Expenditures |
(0.03) | — | 0.00 | (0.05) | |
Net Current Asset Value |
(26.75) | (27.45) | (32.90) | (22.47) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.36 | 0.00 | 0.01 | 0.91 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.05 | 0.09 | |
Average Payables |
1.07 | 1.36 | 0.99 | 1.12 | |
Average Inventory |
0.05 | 0.05 | 0.06 | 0.05 | |
Average Assets |
22.73 | 23.49 | 22.58 | 22.23 | |
Average Common Equity |
(13.22) | (11.89) | (16.66) | (13.58) |
Columns are period end dates · fundamentals updated 6 Nov 2026